Literature DB >> 11098099

Antinociceptive effect of systemic gabapentin in mononeuropathic rats, depends on stimulus characteristics and level of test integration.

V Kayser1, D Christensen.   

Abstract

The anticonvulsant gabapentin is effective against neuropathic pain, but the primary site(s) and mechanism(s) of action are unknown. In order to explore the relative contribution of spinal versus supra-spinal mechanisms to the antinociceptive effect of gabapentin, this study used two differentially integrated nociceptive tests. We systematically compared the effects of various doses of gabapentin on the paw withdrawal to pressure (PWTP), a spinally coordinated reflex and the vocalization threshold to paw pressure (VTPP), a supra-spinal integrated test in the sciatic nerve constriction rat model of neuropathic pain. In addition, we evaluated the effect of gabapentin on the struggle latency to paw immersion into a non-noxious cold (10 degrees C) water bath. Similar lower doses (1-30 mg/kg) of gabapentin produced potent antinociception in the VTPP test but were devoid of effects on the PWTP. The effect was observed not only on the nerve-injured side, but also, although less pronounced, on the contralateral side. Only the highest dose (100 mg/kg) of the anticonvulsant was able to induce an increase in the nerve-injured paw threshold in both tests. In the thermal test, gabapentin (3, 10 and 30 mg/kg i.p.) dose-dependently increased the response time to the 10 degrees C stimulus. Gabapentin at 100 mg/kg but not at 30 mg/kg produced motor deficits in animals using the rotarod test. Taken together, our findings suggest that low doses of gabapentin have a preferential action on the more integrated pain-related behaviour in neuropathic rats. The present results confirm that gabapentin may be a useful approach for the clinical management of several aspects of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11098099     DOI: 10.1016/s0304-3959(00)00307-9

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  7 in total

1.  The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.

Authors:  Valérie Kayser; Bertrand Aubel; Michel Hamon; Sylvie Bourgoin
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Gabapentinoid Insensitivity after Repeated Administration is Associated with Down-Regulation of the α(2)δ-1 Subunit in Rats with Central Post-Stroke Pain Hypersensitivity.

Authors:  Yan Yang; Fei Yang; Fan Yang; Chun-Li Li; Yan Wang; Zhen Li; Yun-Fei Lu; Yao-Qing Yu; Han Fu; Ting He; Wei Sun; Rui-Rui Wang; Jun Chen
Journal:  Neurosci Bull       Date:  2016-01-19       Impact factor: 5.203

3.  Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain.

Authors:  Dong Woo Han; Tae Dong Kweon; Jong Seok Lee; Youn-Woo Lee
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

4.  Antihyperalgesic activity of chlorogenic acid in experimental neuropathic pain.

Authors:  Deniz Bagdas; Nilufer Cinkilic; Hasret Yucel Ozboluk; Musa Ozgur Ozyigit; Mine Sibel Gurun
Journal:  J Nat Med       Date:  2012-12-01       Impact factor: 2.343

5.  Gabapentin reverses central hypersensitivity and suppresses medial prefrontal cortical glucose metabolism in rats with neuropathic pain.

Authors:  Hsiao-Chun Lin; Yu-Hsin Huang; Tzu-Hao Harry Chao; Wen-Ying Lin; Wei-Zen Sun; Chen-Tung Yen
Journal:  Mol Pain       Date:  2014-09-25       Impact factor: 3.395

6.  Analgesic effect of intrathecal gabapentin in a rat model of persistent muscle pain.

Authors:  Tae-Wook Kang; Min Kyun Sohn; Noh Kyoung Park; Sang Hyung Ko; Kyoung Jin Cho; Jaewon Beom; Sangkuk Kang
Journal:  Ann Rehabil Med       Date:  2014-10-30

7.  Methods Used to Evaluate Pain Behaviors in Rodents.

Authors:  Jennifer R Deuis; Lucie S Dvorakova; Irina Vetter
Journal:  Front Mol Neurosci       Date:  2017-09-06       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.